PND99 The Humanistic Disease Burden of Episodic and Chronic Migraine in France, Spain and the United Kingdom

Abstract

Migraine is a disabling disease affecting 14% of the population worldwide. Real-world data were collected on patients with episodic migraine (EM) and chronic migraine (CM) who had failed ≥2 preventive treatments in the United Kingdom, France, and Spain, with a focus here on health-related quality-of-life (HRQoL) outcomes. A cross-sectional, web-based survey was conducted among eligible patients with EM and CM in the United Kingdom, France, and Spain. HRQoL was assessed using the Migraine Disability Assessment (MIDAS) and EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire (assessed for health “today” and during most recent migraine headache). Descriptive statistics were calculated at the country level and qualitatively compared across countries. Patients (n = 316) were included from the United Kingdom (n = 106; 80 EM), France (n = 105; 80 EM), and Spain (n = 106; 80 EM). Of the CM patients, 63% were female, while of the EM patients, 48% were female. CM patients experienced greater migraine disability versus EM patients (median MIDAS score, 30 vs 12). For their most recent migraine, CM patients reported lower health status than EM patients, based on the EQ-5D-5L visual analog scale (median, 40 vs 60) and total index (median, 0.35 vs 0.52) scores. Among EM patients, MIDAS scores were highest in Spain (median, 19) followed by France (13) and the United Kingdom (8). EQ-5D-5L index scores for most recent migraine were comparable across countries (median, United Kingdom, 0.57; Spain, 0.55; France, 0.41). Results reveal substantial migraine disability among patients who have failed previous preventive therapies and that unmet needs may be greater in certain countries.